Category: News Items

ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing Funds will advance the development of ONL1204 Ophthalmic Solution with the initiation of a Phase 2 global study for the treatment of geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) ANN ARBOR, Mich., September 13, 2024 – ONL Therapeutics, Inc., a clinical-stage biopharmaceutical…

ONL Therapeutics To Present At 2024 BIO CEO & Investor Conference ANN ARBOR, Mich., February 6, 2024 – ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, announced today that David Esposito, president and chief executive officer, will present a corporate update at the BIO CEO & Investor…

ONL Therapeutics to Present on ONL1204 in Podium Presentation at the 47th Annual Meeting of the Macula Society  The presentation will review study population data from ONL’s Phase 2 study of ONL1204 Ophthalmic Solution in patients with Macula-Off Rhegmatogenous Retinal Detachment  ANN ARBOR, Mich., January 23, 2024 – ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company…

More than 135 patients recruited in four months for Phase 2 study of a single intravitreal (IVT) injection of ONL1204 Ophthalmic Solution as adjunct to standard-of-care surgery

ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the first patient has been dosed in its Phase 2 clinical trial of ONL1204 Ophthalmic Solution in patients with macula-off rhegmatogenous retinal detachment (RRD).

ONL Therapeutics to Present at the XXVth Biennial Meeting of the International Society for Eye Research Oral presentation will review the scientific rationale for Fas receptor inhibition, a unique mechanism-of-action, in the treatment of patients with progressing open-angle glaucoma (OAG) ANN ARBOR, MI – February 13, 2023 ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel…

ONL Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for ONL1204 Ophthalmic Solution First-in-class small molecule Fas inhibitor with unique mechanism of action is designed to provide neuroprotection for retinal cells ANN ARBOR, MI – February 1, 2023 ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with…

ONL Therapeutics to Highlight New Data in Upcoming Scientific Presentations at the 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research Oral presentations will focus on latest findings for ONL1204 Ophthalmic Solution in patients with geographic atrophy associated with dry age-related macular degeneration ANN ARBOR, MI – January…

AmbioPharm Supports ONL Therapeutics with Peptide Manufacturing to Prepare for IND Application for Phase 2 Study • ONL closed the second tranche of a $46.9 million Series B financing round earlier this year• ONL now preparing IND filing for a Phase 2 study of ONL1204 Ophthalmic Solution• AmbioPharm providing manufacturing support for ONL1204 NORTH AUGUSTA, SC &…